4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been given an average rating of "Moderate Buy" by the ten ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $30.63.

Several brokerages have recently commented on FDMT. HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Friday, March 7th. Chardan Capital reduced their price objective on 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Bank of America cut their price target on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a report on Monday, March 10th. Finally, BMO Capital Markets lowered 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $40.00 to $15.00 in a report on Monday, January 13th.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock traded down $0.04 during trading on Monday, reaching $3.75. 645,936 shares of the company's stock were exchanged, compared to its average volume of 793,441. 4D Molecular Therapeutics has a 1-year low of $3.66 and a 1-year high of $36.25. The company has a market cap of $173.63 million, a P/E ratio of -1.32 and a beta of 2.83. The firm's 50-day moving average price is $4.77 and its 200 day moving average price is $7.60.

Remove Ads

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.10). As a group, equities research analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Decheng Capital LLC grew its position in shares of 4D Molecular Therapeutics by 0.5% during the 4th quarter. Decheng Capital LLC now owns 400,000 shares of the company's stock valued at $2,228,000 after acquiring an additional 2,165 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of 4D Molecular Therapeutics by 7.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company's stock worth $247,000 after purchasing an additional 2,925 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock worth $51,000 after purchasing an additional 3,630 shares in the last quarter. Rhumbline Advisers increased its stake in shares of 4D Molecular Therapeutics by 5.3% in the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock worth $409,000 after purchasing an additional 3,675 shares in the last quarter. Finally, ProShare Advisors LLC increased its stake in shares of 4D Molecular Therapeutics by 30.1% in the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company's stock worth $91,000 after purchasing an additional 3,783 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.